Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAVI C100
PACTR202008822861957Phase 2Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Jan 2019
- Modality
- Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, open-label trial of Teropavimab and zinlirvimab in human immunodeficiency virus infection (HIV) (2 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Grade 2 or higher solicited and investigational-product-related unsolicited adverse events, Grade 3 or higher solicited and investigational-product-related unsolicited adverse events and 2 more. Started Jan 2019; status: completed.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202008822861957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202008822861957.